Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discounts will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
AGC will build a facility at its site in Chiba, Japan, that will use mammalian cell culture to produce antibody-based drugs. The firm, formerly called Asahi Glass, says the plant will be the first in Japan to make such cell culture drugs on a contract basis. AGC has been aggressively expanding its drug contract manufacturing business. In July, it announced the expansion of a small-molecule pharmaceutical chemical plant, also in Chiba. In 2016, AGC acquired the biologics firms Biomeva and CMC Biologics.
This article has been sent to the following recipient: